Department of Internal medicine, Synairgen (United Kingdom), Catholic University of the Sacred Heart, Academic Medical Center, European Federation of Allergy and Airways Diseases Patients Associations, University of Manchester, The Medicines Company (Switzerland), Roche (Switzerland), Aix-Marseille University, AstraZeneca (Sweden), University of Copenhagen, Semmelweis University, Hvidovre Hospital, Umeå University, French National Centre for Scientific Research, Institutszentrum Schloss Birlinghoven, Karolinska Institute, University of Nottingham, Jagiellonian University, University of Southampton, Boehringer Ingelheim (Germany), Innovative Medicines Initiative, University of Bern, UCB Pharma (Belgium), University of Bergen, Chiesi (Italy), Pfizer (United Kingdom), Aerocrine (Sweden), Asthma UK, Imperial College London, Almirall (Spain), University of Catania, Philips (Netherlands), GlaxoSmithKline (United Kingdom)
The inability of pre-clinical studies to predict clinical efficacy is a major bottleneck in drug development. In severe asthma this bottleneck results from: a lack of useful and validated biomarkers, underperforming pre-clinical models, inadequate and incomplete sub-phenotyping, and insufficient disease understanding. The use of biomarker profiles comprised of various types of high-dimensional data, integrated with an innovative systems ...